We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Whats hapened to Ahfam3 most proilific messager not heard from him.
Hope he is ok.
"Let the science talk"
Jeeeez... it would be about time.
Thanks krone. So looks like , if data is great then we are going to attract lots of looks, and now with CHK then looking good. Not even mentioned tyk2 cancer molecule.
Let the science talk
I looked at this SOG and I noticed it said excluding the China region I’m just wondering (wild guess )if it’s because we have the patent granted for China with our tyk2 jak 1 may be totally out mind
GLA
Only one l can see is below
https://www.geneonline.com/biohaven-licenses-tyk2-jak1-dual-inhibitor-from-chinas-highlightll-in-970-million-pact/
I will do some more digging.
Does anyone know if Hangzhou s tyk2 jak1 TLL-018 has been patented in China ? And is this one we can compare against . Ph2 data out mid year for psoriasis Have tried to find out to no avail
GLA
Goid evening Brighty1.
Good post. I can think of no reason as to why 737 cannot progress to a phase 2 combo with LDG and maybe PD-1 inhibitor or similar. Excellent results l believe we're achieved albeit preclinical but l believe would have given GSK Tesaro bought pipeline a run for its money. GSK squeezed their pipeline into Europe as a treatment in an area of unmet need and from memory was not without its problems with regards to safety profile which was under the watch of the EMA..
We would not be the only chk1 inhibitor progressing through trial if and when progress starts again. Addressing the DDR pathway is an extremely important aspect of cancer therapy and l am of the strong impression that although there is competition to get later ideas into development and treatment we have not properly given good potential earlier compounds sufficient chance to eclipse maximum potential.
In combo is the way forward and has been suggested by research groups many times.
Our compound achieved as much as you can expect from the mechanisms of a checkpoint inhibitor working. The compound is fine itself but by the nature of the way CHK1 inhibitor works it needs in combo therapy.
Sareum now have designed and developed their own compound in the area of auto immune. They have decided on the pathways used and the sectivity of the compound. All the molecules in the compounds are patent protected as are the compounds themselves as well as the controls of manufacture and of course very nicely put in a capsular formation.
As an example here to show advantage of capsule formulation has anyone ever experienced the benefit of the Neurofen capsule over the tablet?
Far quicker and more effective.
Regards
Thanks for all the replies. I'd be very wary of these buyouts with a sum up front and then staggered milestones. We all know from SO that strategies can change and milestones are no guarantee of payment.
Contradictory question.
its either a licence agreement (the SP reacts accordingly to initial payment and potential payment and fluctuates as normal over time) or a buy out at a set price - end of .
I guess they might issue a B or C share in the company which would have no intrinsic value as far as a listing price but which would entitle the holder to receive "dividends" equivalent to their proportion of milestone payments received. Something like that anyway. And don't forget that, as shareholders, we get to vote on whether any deal is acceptable to us, so they'd have to explain very clearly how we would be entitled to future payments if the deal was structured in that way.
Hi Ben
In case of a take out say Merger Sareum might keep going as a legal entity listed on AIM but belong to the new owner. Also, in case Sareum goes bust the buyer will pay the billions or lump sum and any party shall being compensated in relation and according to their holding nevertheless keep the ranking in mind. Shareholders will being compensated last after debt are being paid.
Thats my understanding.
Can I ask a question about how these sorts of deals work in practice?
Say we are bought for £500m upfront and up to £1bn in milestones. How does that work? How would they pay the subsequent money for milestones if the company doesn't exist more? Would our shares still technically be active? So it would officially be a buyout as SAR would have 0 control over operations but the shares still bought and sold? I can't quite understand how we are bought out but as shareholders be owed money potentially 2 years down the line...
The relevance of Brighty's posts in relation to these deals is to bring to our attention the types of deals happening within our sector. So the value of any potential deal for Sareum is subjective to say the least. Brighty's links gives us all an idea of what is out there. The rest is down to the number of shares in circulation. So a £730m deal for Sareum would equate to £10 per share. It is up to investors what futuristic value they would put on 737, 1801 success and 1802 success. If £2/£3 per share is your target then thats fine and would value Sareum at £146m or £219m respectively.
Brightys email suggests deals of a much higher value should be at least considered if Sareum were to prove successful. I am sure you can all do the arithmetic and I would suggest this is the reason for the enthusiasm and quiet optimism for a high share price on any takeover or license deals.
Only patience will win the day on AIM for the ultimate prize but nothing wrong with cashing out along the way.
Sflf isn't invested here.
Meanwhile, in San Francisco, Sareum is rubbing shoulders with thousands of would-be investors at the JPM Healthcare conference.
We certainly have more to bring to everyone’s attention than last year - you never know!
Taken from the recent MarketWatch article: The British pharmaceutical giant said Tuesday that the deal to buy San Francisco and London-based Aiolos Bio, which focuses on patients with respiratory and inflammatory conditions, includes a Phase 2-ready antibody called AIO-001 for the treatment of adult patients with certain respiratory and inflammatory conditions.
Before dissing the Billion Pound deals in our space don't forget that in addition to the ongoing trials with SDC1801 and plans for SDC1802 we already have a P1 candidate with SRA737. Before Sierra sat on it for a couple of years (in favour of its other lead drug) SRA737 was being hailed as "lethal to cancer cells" and could "have utility as a monotherapy in a range of tumor indications". That's pretty big in our sector. This is why in due course SAR could be a Billion takeover target, especially when you then add SDC1801 and SDC1802 in to the mix. SRA737 might yet blindside many of the doubters on here if our new JV partner in the USA can develop the "lethal to cancer cells" data. How much would that be worth??....
Good luck, Brighty
Aiolos had received around $250 million in funding, around 10X our level. So far more mature than we are. Imagine the dilution should we end up with that level of funding prior prior to being taken out. We'd be back at a penny stock. There's no certainty here for SAR and no direct read across to SAR on these $1bln acquisitions that are being made. Most of these companies are far more advanced and have huge amounts of debt.
Another £1 Billion + deal in our sector today, with GSK paying $1 billion upfront and up to $400 million in certain success-based regulatory milestone payments for Aiolos Bio. One day this could be SAR.....
Good luck, Brighty
Apologies for what may be a sunny question but where are we progress/trial status wise in comparison to the recent deals being signed with the small bios? I get a little confused at how certain bios appear to be massively valued against where we sit and believe to be undervalued. Thanks I’m advance for any clarity cheers. HNY and GLA for this year!
A good read, one word that’s wrong though, that is the word Pandemic, more like Plandemic. :)
Jan 8
Johnson & Johnson and Merck on Monday
announced plans to buy cancer therapy developers on the first
day of a major U.S. healthcare conference, igniting what
industry participants hope will be a strong year for deals after
a solid end to 2023.
Deals announced on Monday had a combined equity value of
more than $6 billion, including one by medical device maker
Boston Scientific BSX.N for Axonics Inc AXNX.O . That follows
roughly $25 billion worth of U.S.-listed biotech deals last
month, according to data provider LSEG Deals Intelligence.
Meanwhile, over 8,000 people are gathering at the JPMorgan
healthcare conference in San Franscisco, in another sign of a
return to business as usual after the COVID-19 pandemic.
Global pharma companies' efforts to replace revenue from
older drugs with promising new ones were largely stymied in
2023, but looming patent expirations and easing financing costs
are setting up 2024 well, industry sources say.
On Monday, J&J JNJ.N said it would buy Ambrx Biopharma
AMAM.O for $2 billion to gain promising targeted cancer
therapies known as antibody drug conjugates (ADC).
The deal gets "the ball rolling on what seems to be a strong
start for M&A in 2024", said Citi analyst Joanne Wuensch.
Interest in these drugs has spiked and several related
companies have been acquired in recent months, including
ImmunoGen IMGN.O by AbbVie ABBV.N and Seagen by Pfizer
PFE.N .
Separately, Merck MRK.N said it would buy cancer drug
developer Harpoon Therapeutics HARP.O for about $680 million,
gaining access to early-stage immunotherapies being tested for
lung cancer and multiple myeloma.
Certainly we know the Pharma mega caps have cash to spend and pipelines to rebuild.
KR
ZA
It's just above your house.......May I suggest moving?
I keep seeing it, every time I look up on a clear day it';s there.
I wonder whether anyone else sees it or whether it just sits there above my house.
That bloody big pie in the sky!